Form 4: Lixte Biotechnology Director Receives RSUs
Statement of Changes in Beneficial Ownership
Michael Holloway, a Director at Lixte Biotechnology Holdings, Inc., received 15,000 restricted share units (RSUs) that have vested.
Summary
- Michael Andrew Holloway, a Director at Lixte Biotechnology Holdings, Inc., was granted 15,000 restricted share units (RSUs) on July 1, 2026.
- These RSUs vested upon the satisfaction of performance conditions outlined in his RSU agreement.
- Each RSU represents a contingent right to receive one share of common stock upon vesting.
- Following this transaction, Holloway beneficially owns 40,000 RSUs, which includes the newly awarded 15,000 RSUs and 25,000 previously vested RSUs.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral filing, as it reports on routine equity grants and vesting for a director, which is standard corporate practice and does not inherently signal significant positive or negative developments.
Positives
- Director Michael Holloway received a grant of 15,000 RSUs, indicating continued incentive alignment with the company's performance.
- The RSUs have vested, signifying that performance conditions have been met.
- The total beneficial ownership of RSUs for the director is 40,000, showing a significant stake.
Future Outlook
The filing does not contain forward-looking statements or guidance.
Industry Context
StockSavvy.ai notes that the issuance of RSUs to directors is a common practice in the biotechnology sector to align executive compensation with long-term company performance and shareholder value.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Equity Incentive Plan | RSUs were granted pursuant to the Lixte Biotechnology Holdings, Inc. 2020 Stock Incentive Plan. | Not specified, but plan is from 2020 | Standard practice for incentivizing key personnel and aligning interests with shareholders. |
Stakeholder Impact
- Shareholders: The grant and vesting of RSUs align director incentives with shareholder interests, potentially driving long-term value creation.
- Employees: The existence of the 2020 Stock Incentive Plan suggests a framework for employee equity participation, though this specific filing pertains only to a director.
Key Dates
| Date | Description |
|---|---|
| 07/01/2026 | Earliest transaction date and date of RSU grant and vesting. |
| 07/02/2026 | Date of signature on the filing. |
Keywords
Form 4, SEC Filing, Lixte Biotechnology Holdings, LIXT, Director, Restricted Share Units, RSUs, Beneficial Ownership, Stock Incentive Plan, Vesting
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.